During the last session, G1 Therapeutics Inc (NASDAQ:GTHX)’s traded shares were 0.59 million, with the beta value of the company hitting 1.80. At the end of the trading day, the stock’s price was $4.53, reflecting an intraday loss of -3.21% or -$0.15. The 52-week high for the GTHX share is $6.14, that puts it down -35.54 from that peak though still a striking 76.16% gain since the share price plummeted to a 52-week low of $1.08. The company’s market capitalization is $236.83M, and the average trade volume was 1.46 million shares over the past three months.
G1 Therapeutics Inc (NASDAQ:GTHX) trade information
G1 Therapeutics Inc (GTHX) registered a -3.21% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -3.21% in intraday trading to $4.53, hitting a weekly high. The stock’s 5-day price performance is -5.03%, and it has moved by 8.63% in 30 days. Based on these gigs, the overall price performance for the year is 63.54%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
G1 Therapeutics Inc (GTHX) estimates and forecasts
Statistics show that G1 Therapeutics Inc has outperformed its competitors in share price, compared to the industry in which it operates. G1 Therapeutics Inc (GTHX) shares have gone up 177.91% during the last six months, with a year-to-date growth rate more than the industry average at 41.94% against 14.10. In the rating firms’ projections, revenue will decrease -12.40% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 16.45M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 18.01M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 42.39M and 12.3M respectively. In this case, analysts expect current quarter sales to shrink by -61.20% and then jump by 46.40% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 18.38%. While earnings are projected to return 41.42% in 2024.
GTHX Dividends
G1 Therapeutics Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
